Researchers have published new findings that may lead to a new standard of care for patients with locally advanced cervical cancer. The phase one study found that a new chemotherapy medicine, Triapine, was well tolerated in combination with standard-of-care cisplatin chemotherapy and radiation treatment in women with cervical cancer. This regimen provided both significant reduction in cancer disease and cancer control.